Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Rofecoxib Significantly Reduces The Risk Of Recurrence Of Colorectal Polyps

01.09.2006
Data from the APPROVe Trial Shows Rofecoxib Effective in Broad, At-Risk Population

The use of the cyclooxygenase-2 (COX-2) inhibitor rofecoxib (Vioxx®) reduces the risk of colorectal adenomas, according to data being published in Gastroenterology, the journal for the members of the American Gastroenterological Association (AGA). The study, “A Randomized Trial of Rofecoxib for the Chemoprevention of Colorectal Adenomas,” is scheduled for publication in December, but was released on-line in August due to the significance of the findings. The manuscript can be found on-line.

John Baron, MD, lead author of the paper and a professor at Dartmouth Medical School, has been studying chemoprevention of colorectal cancer for more than twenty years. “These are exciting findings,” he said. “They show once again the potential for non-steroidal anti-inflammatory drugs, or NSAIDs, to interfere with the development of cancer in the colon and rectum.”

Extensive data have suggested previously that aspirin and non-selective nonsteroidal anti-inflammatory drugs (NSAIDs) could reduce colon cancer risk. This study now demonstrates such an effect for a selective COX-2 inhibitor in a placebo-controlled randomized study. While previous randomized studies have shown that COX-2 inhibitors can lower the risk of adenoma in patients with a rare genetic syndrome called familial adenomatous polyposis (FAP), the effect in the broad population of people at risk for colorectal cancer has not been previously demonstrated. More commonly referred to as “polyps,” adenomas are benign tumors that are precursors to colon cancer, and are commonly found in older adults in the United States and worldwide.

The APPROVe (Adenomatous Polyp Prevention on Vioxx) study was a randomized, placebo-controlled, double-blind trial funded by Merck Research Laboratories. Study results showed that patients taking rofecoxib had a lower recurrence rate of adenomas than those taking placebo (41 percent vs 55 percent; p

About the Study

The study included 2,587 evaluable patients with a recent history of confirmed colorectal polyps followed at 108 sites in the United States and abroad. After removal of all polyps, patients were randomized to receive either placebo or 25 mg rofecoxib (the average daily recommended dose) on a daily basis. The primary endpoint was all polyps diagnosed during the three-year treatment period based upon colonoscopies conducted one year and three years after baseline. In addition, an extension to the APPROVe study was conducted to assess recurrence of adenomas in the year following the end of the three years’ treatment through colonoscopy at year four.

Patients treated with rofecoxib experienced more serious adverse events, including significant upper gastrointestinal events and, as reported previously, increased risks of thrombotic cardiovascular events (Bresalier et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. NEJM 2005;352:1092-102). Dr. Baron does not believe that the side effects will derail the eventual development of effective chemoprevention.

“While the toxicity of the currently available COX-2 inhibitors may be problematic, the demonstration of efficacy certainly implies that other agents may be suitable for longer term use,” he said.

Although it is not known how rofecoxib interferes with carcinogenesis, inhibition of COX-2 has been thought to play a role. Other mechanisms are possible, however, and scientists are actively seeking to understand exactly how non-steroidal anti-inflammatory drugs alter pathways that lead to cancer.

“Colorectal cancer is the second leading cause of cancer death in the United States1, so it is important to aggressively research and develop potential chemopreventive agents to help patients who are at the highest risk of developing the disease,” according to Anil K. Rustgi, MD, editor of Gastroenterology and Chief of Gastroenterology at the University of Pennsylvania School of Medicine. “It is important to not hold onto this information until December so the results of this study can be added to the body of knowledge about cancer prevention that could potentially help physicians care for their patients.”

About Colorectal Cancer

Colorectal cancer is the third most common cancer in men and women2 and the second leading cause of cancer death1. However it is one of the most easily prevented cancers, and has a relatively good prognosis when diagnosed and treated early. An individual’s risk of colon cancer increases with age, therefore, all men and women should undergo a baseline colonoscopy at age 50, then again at the recommendation of their gastroenterologist. Eighty to 90 million Americans (approximately 25 percent of the US population) are considered at risk because of age or other factors, and more women over the age of 75 die from colorectal cancer than from breast cancer3.

About the AGA Institute

The American Gastroenterological Association (AGA) is dedicated to the mission of advancing the science and practice of gastroenterology. Founded in 1897, the AGA is one of the oldest medical-specialty societies in the United States. Comprised of two non-profit organizations—the AGA and the AGA Institute—our more than 15,000 members include physicians and scientists who research, diagnose and treat disorders of the gastrointestinal tract and liver. The AGA, a 501(c6) organization, administers all membership and public policy activities, while the AGA Institute, a 501(c3) organization, runs the organization’s practice, research and educational programs. On a monthly basis, the AGA Institute publishes two highly respected journals, Gastroenterology and Clinical Gastroenterology and Hepatology. The organization's annual meeting is Digestive Disease Week®, which is held each May and is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. For more information, please visit www.gastro.org.

About Gastroenterology

Gastroenterology, the official journal of the AGA Institute, is the most prominent journal in the subspecialty and is in the top one percent of indexed medical journals internationally. The journal publishes clinical and basic science studies of all aspects of the digestive system, including the liver and pancreas, as well as nutrition. The journal is abstracted and indexed in Biological Abstracts, CABS, Chemical Abstracts, Current Contents, Excerpta Medica, Index Medicus, Nutrition Abstracts and Science Citation Index. For more information, visit www.gastrojournal.org.

About Clinical Gastroenterology and Hepatology

The mission of Clinical Gastroenterology and Hepatology is to provide readers with a broad spectrum of themes in clinical gastroenterology and hepatology. This monthly peer-reviewed journal includes original articles as well as scholarly reviews, with the goal that all articles published will be immediately relevant to the practice of gastroenterology and hepatology. For more information, visit www.cghjournal.org.

Aimee Frank | EurekAlert!
Further information:
http://www.gastro.org

More articles from Health and Medicine:

nachricht Unique brain 'fingerprint' can predict drug effectiveness
11.07.2018 | McGill University

nachricht Direct conversion of non-neuronal cells into nerve cells
03.07.2018 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: First evidence on the source of extragalactic particles

For the first time ever, scientists have determined the cosmic origin of highest-energy neutrinos. A research group led by IceCube scientist Elisa Resconi, spokesperson of the Collaborative Research Center SFB1258 at the Technical University of Munich (TUM), provides an important piece of evidence that the particles detected by the IceCube neutrino telescope at the South Pole originate from a galaxy four billion light-years away from Earth.

To rule out other origins with certainty, the team led by neutrino physicist Elisa Resconi from the Technical University of Munich and multi-wavelength...

Im Focus: Magnetic vortices: Two independent magnetic skyrmion phases discovered in a single material

For the first time a team of researchers have discovered two different phases of magnetic skyrmions in a single material. Physicists of the Technical Universities of Munich and Dresden and the University of Cologne can now better study and understand the properties of these magnetic structures, which are important for both basic research and applications.

Whirlpools are an everyday experience in a bath tub: When the water is drained a circular vortex is formed. Typically, such whirls are rather stable. Similar...

Im Focus: Breaking the bond: To take part or not?

Physicists working with Roland Wester at the University of Innsbruck have investigated if and how chemical reactions can be influenced by targeted vibrational excitation of the reactants. They were able to demonstrate that excitation with a laser beam does not affect the efficiency of a chemical exchange reaction and that the excited molecular group acts only as a spectator in the reaction.

A frequently used reaction in organic chemistry is nucleophilic substitution. It plays, for example, an important role in in the synthesis of new chemical...

Im Focus: New 2D Spectroscopy Methods

Optical spectroscopy allows investigating the energy structure and dynamic properties of complex quantum systems. Researchers from the University of Würzburg present two new approaches of coherent two-dimensional spectroscopy.

"Put an excitation into the system and observe how it evolves." According to physicist Professor Tobias Brixner, this is the credo of optical spectroscopy....

Im Focus: Chemical reactions in the light of ultrashort X-ray pulses from free-electron lasers

Ultra-short, high-intensity X-ray flashes open the door to the foundations of chemical reactions. Free-electron lasers generate these kinds of pulses, but there is a catch: the pulses vary in duration and energy. An international research team has now presented a solution: Using a ring of 16 detectors and a circularly polarized laser beam, they can determine both factors with attosecond accuracy.

Free-electron lasers (FELs) generate extremely short and intense X-ray flashes. Researchers can use these flashes to resolve structures with diameters on the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Leading experts in Diabetes, Metabolism and Biomedical Engineering discuss Precision Medicine

13.07.2018 | Event News

Conference on Laser Polishing – LaP: Fine Tuning for Surfaces

12.07.2018 | Event News

11th European Wood-based Panel Symposium 2018: Meeting point for the wood-based materials industry

03.07.2018 | Event News

 
Latest News

Leading experts in Diabetes, Metabolism and Biomedical Engineering discuss Precision Medicine

13.07.2018 | Event News

Research finds new molecular structures in boron-based nanoclusters

13.07.2018 | Materials Sciences

Algae Have Land Genes

13.07.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>